We have shown that somatic PTPN11 mutations increase proliferation, activate the Shp2 phosphatase domain, and promote the activation of the PI3K and MAPK pathways in NSCLC cell lines, which is consistent with prior studies in leukaemia [8,9,11,14,29,30]. The gene discussed is PTPN11; the disease is leukemia.